{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T12:43:30Z","timestamp":1772369010529,"version":"3.50.1"},"reference-count":16,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2014,3,1]],"date-time":"2014-03-01T00:00:00Z","timestamp":1393632000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2014,3]]},"DOI":"10.1016\/j.ygyno.2014.01.027","type":"journal-article","created":{"date-parts":[[2014,1,23]],"date-time":"2014-01-23T00:30:20Z","timestamp":1390437020000},"page":"537-541","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"title":["Prognostic and predictive value of the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) score in surgery for recurrent ovarian cancer"],"prefix":"10.1016","volume":"132","clinical-trial-number":[{"clinical-trial-number":"nct01166737","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Philipp","family":"Harter","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bianca","family":"Beutel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Piero F.","family":"Alesina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dietmar","family":"Lorenz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andre","family":"Boergers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florian","family":"Heitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rita","family":"Hils","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Kurzeder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Traut","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8477-506X","authenticated-orcid":false,"given":"Andreas","family":"du Bois","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2014.01.027_bb0005","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.ygyno.2011.02.014","article-title":"Impact of a structured quality management program on surgical outcome in primary advanced ovarian cancer","volume":"121","author":"Harter","year":"2011","journal-title":"Gynecol Oncol"},{"issue":"26","key":"10.1016\/j.ygyno.2014.01.027_bb0010","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1056\/NEJMoa1104390","article-title":"Incorporation of bevacizumab in the primary treatment of ovarian cancer","volume":"365","author":"Burger","year":"2011","journal-title":"N Engl J Med"},{"issue":"26","key":"10.1016\/j.ygyno.2014.01.027_bb0015","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1056\/NEJMoa1103799","article-title":"A phase 3 trial of bevacizumab in ovarian cancer","volume":"365","author":"Perren","year":"2011","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.ygyno.2014.01.027_bb0020","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1002\/cncr.24149","volume":"115","author":"du Bois","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2014.01.027_bb0025","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1586\/era.09.165","article-title":"Systemic therapy in recurrent ovarian cancer: current treatment options in new drugs","volume":"10","author":"Harter","year":"2010","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.ygyno.2014.01.027_bb0030","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1093\/annonc\/mdq352","article-title":"Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer: outcomes in the partially platinum-sensitive (platinum-free interval 6\u201312months) subpopulation of OVA-301 phase III randomized trial","volume":"22","author":"Poveda","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ygyno.2014.01.027_bb0035","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1200\/JCO.2012.42.0505","article-title":"OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer","volume":"30","author":"Aghajanian","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2014.01.027_bb0040","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1586\/era.09.49","article-title":"Role of cytoreductive surgery in recurrent ovarian cancer","volume":"7","author":"Harter","year":"2009","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.ygyno.2014.01.027_bb0045","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.ygyno.2008.08.033","article-title":"Cytoreductive surgery for recurrent ovarian cancer: a meta-analysis","volume":"112","author":"Bristow","year":"2009","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2014.01.027_bb0050","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1245\/s10434-006-9058-0","article-title":"Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial","volume":"13","author":"Harter","year":"2006","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ygyno.2014.01.027_bb0055","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1097\/IGC.0b013e31821bb8aa","article-title":"Clinical trials in recurrent ovarian cancer","volume":"21","author":"Friedlander","year":"2011","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.ygyno.2014.01.027_bb0060","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1097\/IGC.0b013e31820aaafd","article-title":"Prospective validation study of a predictive score for operability of recurrent ovarian cancer: the Multicenter Intergroup Study DESKTOP II. A project of the AGO Kommission OVAR, AGO Study Group, NOGGO, AGO-Austria, and MITO","volume":"21","author":"Harter","year":"2011","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.ygyno.2014.01.027_bb0065","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1097\/01.sla.0000133083.54934.ae","article-title":"Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey","volume":"240","author":"Dindo","year":"2004","journal-title":"Ann Surg"},{"issue":"6","key":"10.1016\/j.ygyno.2014.01.027_bb0070","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1002\/jso.21652","article-title":"Role of secondary cytoreductive surgery in ovarian cancer relapse: who will benefit? A systematic analysis of 240 consecutive patients","volume":"102","author":"Sehouli","year":"2010","journal-title":"J Surg Oncol"},{"issue":"9","key":"10.1016\/j.ygyno.2014.01.027_bb0075","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1002\/cncr.21845","article-title":"Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum-sensitive epithelial ovarian carcinoma","volume":"106","author":"Chi","year":"2006","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.ygyno.2014.01.027_bb0080","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1245\/s10434-009-0357-0","article-title":"Surgery for recurrent ovarian cancer: role of peritoneal carcinomatosis: exploratory analysis of the DESKTOP I Trial about risk factors, surgical implications, and prognostic value of peritoneal carcinomatosis","volume":"16","author":"Harter","year":"2009","journal-title":"Ann Surg Oncol"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825814000432?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825814000432?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,7]],"date-time":"2018-10-07T00:55:18Z","timestamp":1538873718000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825814000432"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3]]},"references-count":16,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,3]]}},"alternative-id":["S0090825814000432"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2014.01.027","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2014,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prognostic and predictive value of the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) score in surgery for recurrent ovarian cancer","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2014.01.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}